AngioInsight

Executive Summary

AngioInsight is a Cambridge, MA-based medical AI company developing AngioAI+™, a software platform that analyzes standard angiographic videos to help clinicians diagnose and manage Coronary Artery Disease (CAD) and Coronary Microvascular Disease (CMD). Unlike traditional catheter-based pressure wire measurements, AngioAI+™ provides image-based physiological assessments without requiring additional hardware during angiography, potentially reducing procedure time, cost, and risk. The platform addresses a significant unmet need: CMD is often undiagnosed due to lack of practical diagnostic tools, yet it affects millions of patients with angina and no obstructive CAD. AngioInsight's technology aims to democratize access to advanced hemodynamic assessment, enabling more precise diagnosis and treatment planning in cath labs worldwide. AngioInsight was founded in 2018 and has reached key early milestones, including algorithm development and preliminary clinical validation. The company is now seeking FDA 510(k) clearance and preparing for a pivotal clinical study to support its regulatory submission. If approved, AngioAI+™ could become a standard tool in interventional cardiology, offering a software-only upgrade to existing angiography systems. However, the company faces risks common to early-stage medtech: regulatory hurdles, competition from established players like Philips and Medis, and the need for commercial partnerships. Overall, AngioInsight represents a promising but speculative investment opportunity in the AI-enabled cardiovascular diagnostics space.

Upcoming Catalysts (preview)

• Q4 2026FDA 510(k) clearance for AngioAI+™ in CAD indication60% success
• Q2 2026Publication of pivotal clinical study results for CMD diagnosis70% success
• TBDStrategic partnership or licensing deal with a major cardiovascular device manufacturer40% success